For the Inventor, By the Inventor

Enter assignee name

Chiesi Farmaceutici S.p.a.

USPTO Granted Patents = 329

CIPO Patents = 271

EPO Patents = 221

Trademarks = 51

Forward Citations = 1,828

Loading Chart...

Loading Chart...

570 inventors (with patents filed for the assignee):

Elisabetta Armani (57 out of 57 patents)

Gabriele Amari (48 out of 48 patents)

Paolo Chiesi (38 out of 41 patents)

4. Carmelida Capaldi (28 out of 28 patents)

5. Gaetano Brambilla (24 out of 28 patents)

6. Paolo Ventura (24 out of 27 patents)

7. Fabio Rancati (19 out of 19 patents)

8. Andrea Rizzi (19 out of 19 patents)

9. Maurizio Delcanale (19 out of 19 patents)

10. Fausto Pivetti (18 out of 18 patents)

11. David Andrew Lewis (17 out of 17 patents)

12. Lilian Alcaraz (15 out of 15 patents)

13. Brian John Meakin (14 out of 14 patents)

14. Andrew Stephen Robert Jennings (14 out of 15 patents)

15. Christopher Hurley (14 out of 28 patents)

Core Competencies:

ALK5 Inhibitors

P2X3 Inhibitors

LPA Receptor Inhibitors

Metered Dose Inhalers

Nanoparticles

Aerosol Formulation

Dry Powder Formulations

Rho-Kinase Inhibitors

Pharmaceutical Compositions

Combination Therapy

Pulmonary Administration

Ischemic Event Prevention

329 patents: Sort by Forward Citations

1. 12491156 - Carrier particles for dry powder formulations for inhalation (2025-12-09),

2. 12479826 - Pyridazinyl amino derivatives as ALK5 inhibitors (2025-11-25),

3. D1101930 - Electronic module for metered dose inhalers (2025-11-11),

4. 12466820 - Amino quinazoline derivatives as P2X3 inhibitors (2025-11-11),

5. 12454530 - Amido cyclohexane acid derivatives as LPA receptor inhibitors (2025-10-28),

6. D1097116 - Metered dose inhaler with electronic module (2025-10-07),

7. 12404270 - Quinazoline derivatives as LPA receptor 2 inhibitors (2025-09-02),

8. 12383507 - Clevidipine nanoparticles and pharmaceutical compositions thereof (2025-08-12),

9. 12378293 - Production of nerve growth factor (NGF) and of muteins thereof (2025-08-05),

10. 12357568 - Aerosol formulation for COPD (2025-07-15),

11. 12214129 - Laryngeal mask airway device and method for administering a medicament through a laryngeal mask airway device (2025-02-04),

12. 12097329 - Apparatus to administer drugs to mechanically ventilated patients (2024-09-24),

13. 12016851 - Modified release pharmaceutical formulations comprising deferiprone (2024-06-25),

14. 12016850 - Modified release pharmaceutical formulations comprising deferiprone (2024-06-25),

15. 11981639 - Process for the preparation of a PDE4 inhibitor (2024-05-14),

Chiesi Farmaceutici S.p.A. is an international research-focused pharmaceutical company specializing in respiratory, neonatology, rare diseases, and special care. With a commitment to improving patient outcomes and quality of life, Chiesi develops innovative solutions and medicines that address unmet medical needs. Headquartered in Parma, Italy, Chiesi has a global presence across 27 countries, employing over 6,000 people worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

329 Patents

#1 in Parma

#18 in Italy

#2,659 in the World

Chiesi Farmaceutici S.p.a.

Forward Citations = 1,828

570 inventors:

Elisabetta Armani (57 out of 57 patents)

Gabriele Amari (48 out of 48 patents)

Paolo Chiesi (38 out of 41 patents)

4. Carmelida Capaldi (28 out of 28 patents)

5. Gaetano Brambilla (24 out of 28 patents)

Please report any incorrect information to support@idiyas.com

Loading…